ABSTRACT

In order to replace well-established colloidal carriers such emulsions, liposomes, and polymeric micro- and nanoparticles, solid lipid nanoparticles (SLN) were first created in late 1991. In the rapidly expanding field of nanotechnology, solid lipid nanoparticles are at the vanguard and have several potential applications in clinical therapy, drug delivery, and research, as well as in a wide range of other sciences. Due to their unique size-dependent properties, lipid nanoparticles have the potential to develop innovative therapeutics. The ability to incorporate pharmaceuticals into Nano carriers has given medicine delivery a new prototype; this prototype could be used for secondary and tertiary levels of drug targeting. This paper examines a variety of solid lipid nanoparticles and discusses their advantages, disadvantages, and potential remedies. Solid lipid nanoparticles can be produced in a variety of ways and for a variety of purposes on a large scale. Aspects of biodistribution and solid lipid nanoparticle dosage are also discussed. Keywords: homogenization, TEM, PCS, biodistribution, solid lipid nanoparticles (SLN), colloidal drug carriers, and targeting
Publication date: 01/12/2024

https://ijbpas.com/pdf/2024/December/MS_IJBPAS_2024_8011.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.12.8011